Martin Babler, Esker CEO

Fore­site re­cruits Prin­cip­ia vet Mar­tin Babler — and his old team — to oc­cu­py the C-suite of a start­up

Al­most a year to the day af­ter Sanofi closed on its $3.7 bil­lion Prin­cip­ia buy­out, hand­ing CEO Mar­tin Babler $81 mil­lion for his chunk of eq­ui­ty, the biotech ex­ec is end­ing his sab­bat­i­cal and get­ting back to the helm of a start­up. And he’s bring­ing the old Prin­cip­ia team along with him for the R&D scrim­mage ahead.

Babler is tak­ing over the top post at Es­ker Ther­a­peu­tics from June Lee, who helped found the up­start, which Fore­site hatched out of its labs and en­dowed with a $70 mil­lion launch round. The im­munol­o­gy spe­cial­ist broke out of stealth mode back in May with a tiny staff and a Phase I plan for a TYK2 drug — ini­tial­ly for pso­ri­a­sis — part of its plan to ad­dress ge­net­i­cal­ly de­fined pa­tient groups in a field dom­i­nat­ed by block­busters and block­buster wannabes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.